Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSyent Announces Launch of New FeraMAX Pd Maintenance 45","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Hematology","graph2":"Approved"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSyent Launches Inofolic\u00ae for Women with Polycystic Ovary Syndrome (PCOS)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioSyent Announces Extension of RepaGyn\u00ae and Proktis-M\u00ae Agreement","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"BIOSYENT PHARMA INC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioSyent In-Licenses Endocrinology Product for Canada","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by BIOSYENT PHARMA INC

    Menu

    BIOSYENT PHARMA INC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              BIOSYENT PHARMA INC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioSyent In-Licenses Endocrinology Product for Canada

              Details:

              Under the licensing agreement, BioSyent aims to market, sell & distribute a new endocrinology product in Canada. BioSyent and its European partner will seek Health Canada approval by the end of 2024.

              Lead Product(s): Undisclosed

              Therapeutic Area: Endocrinology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Recipient: Undisclosed

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 12, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BIOSYENT PHARMA INC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement

              Details:

              Under the agreement, BioSyent extended its agreement with its European partner for the RepaGyn (sodium hyaluronate) and Proktis-M products, extending its exclusive Canadian rights to these products until 2032.

              Lead Product(s): Sodium Hyaluronate

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Repagyn

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 15, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BIOSYENT PHARMA INC

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)

              Details:

              Inofolic is a natural health product, combining myo-inositol and folic acid in a unique soft-gel capsule for women living with PCOS. Inofolic® helped 70% of women with PCOSii to regulate their menstrual cycles throughout the 16-week study period.

              Lead Product(s): Inositol,Folic Acid

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Inofolic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BIOSYENT PHARMA INC

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioSyent Announces Launch of New FeraMAX Pd Maintenance 45

              Details:

              FeraMAX (polydextrose iron complex) Maintenance 45 is designed to prevent iron deficiency, maintain healthy iron levels and to address a gap of iron health in women’s health and the management of iron health across various life stages.

              Lead Product(s): Polydextrose Iron Complex

              Therapeutic Area: Hematology Product Name: FeraMAX

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY